Cargando…

Activity in nodose ganglia neurons after treatment with CP 55,940 and cholecystokinin

Previous work has shown that cannabinoids increase feeding, while cholecystokinin (CCK) has an anorexigenic effect on food intake. Receptors for these hormones are located on cell bodies of vagal afferent nerves in the nodose ganglia. An interaction between CCK and endocannabinoid receptors has been...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnston, Juliane R., Freeman, Kimberly G., Edwards, Gaylen L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278814/
https://www.ncbi.nlm.nih.gov/pubmed/30512249
http://dx.doi.org/10.14814/phy2.13927
_version_ 1783378436186701824
author Johnston, Juliane R.
Freeman, Kimberly G.
Edwards, Gaylen L.
author_facet Johnston, Juliane R.
Freeman, Kimberly G.
Edwards, Gaylen L.
author_sort Johnston, Juliane R.
collection PubMed
description Previous work has shown that cannabinoids increase feeding, while cholecystokinin (CCK) has an anorexigenic effect on food intake. Receptors for these hormones are located on cell bodies of vagal afferent nerves in the nodose ganglia. An interaction between CCK and endocannabinoid receptors has been suggested. The purpose of these studies is to explore the effect of pretreatment with a cannabinoid agonist, CP 55,940, on nodose neuron activation by CCK. To determine the effect of CP 55,940 and CCK on neuron activation, rats were anesthetized and nodose ganglia were excised. The neurons were dissociated and placed in culture on coverslips. The cells were treated with media; CP 55,940; CCK; CP 55,940 followed by CCK; or AM 251, a CB1 receptor antagonist, and CP 55,940 followed by CCK. Immunohistochemistry was performed to stain the cells for cFos as a measure of cell activation. Neurons were identified using neurofilament immunoreactivity. The neurons on each slip were counted using fluorescence imaging, and the number of neurons that were cFos positive was counted in order to calculate the percentage of activated neurons per coverslip. Pretreatment with CP 55,940 decreased the percentage of neurons expressing cFos‐immunoreactivity in response to CCK. This observation suggests that cannabinoids inhibit CCK activation of nodose ganglion neurons.
format Online
Article
Text
id pubmed-6278814
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-62788142018-12-10 Activity in nodose ganglia neurons after treatment with CP 55,940 and cholecystokinin Johnston, Juliane R. Freeman, Kimberly G. Edwards, Gaylen L. Physiol Rep Original Research Previous work has shown that cannabinoids increase feeding, while cholecystokinin (CCK) has an anorexigenic effect on food intake. Receptors for these hormones are located on cell bodies of vagal afferent nerves in the nodose ganglia. An interaction between CCK and endocannabinoid receptors has been suggested. The purpose of these studies is to explore the effect of pretreatment with a cannabinoid agonist, CP 55,940, on nodose neuron activation by CCK. To determine the effect of CP 55,940 and CCK on neuron activation, rats were anesthetized and nodose ganglia were excised. The neurons were dissociated and placed in culture on coverslips. The cells were treated with media; CP 55,940; CCK; CP 55,940 followed by CCK; or AM 251, a CB1 receptor antagonist, and CP 55,940 followed by CCK. Immunohistochemistry was performed to stain the cells for cFos as a measure of cell activation. Neurons were identified using neurofilament immunoreactivity. The neurons on each slip were counted using fluorescence imaging, and the number of neurons that were cFos positive was counted in order to calculate the percentage of activated neurons per coverslip. Pretreatment with CP 55,940 decreased the percentage of neurons expressing cFos‐immunoreactivity in response to CCK. This observation suggests that cannabinoids inhibit CCK activation of nodose ganglion neurons. John Wiley and Sons Inc. 2018-12-04 /pmc/articles/PMC6278814/ /pubmed/30512249 http://dx.doi.org/10.14814/phy2.13927 Text en © 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of The Physiological Society and the American Physiological Society This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Johnston, Juliane R.
Freeman, Kimberly G.
Edwards, Gaylen L.
Activity in nodose ganglia neurons after treatment with CP 55,940 and cholecystokinin
title Activity in nodose ganglia neurons after treatment with CP 55,940 and cholecystokinin
title_full Activity in nodose ganglia neurons after treatment with CP 55,940 and cholecystokinin
title_fullStr Activity in nodose ganglia neurons after treatment with CP 55,940 and cholecystokinin
title_full_unstemmed Activity in nodose ganglia neurons after treatment with CP 55,940 and cholecystokinin
title_short Activity in nodose ganglia neurons after treatment with CP 55,940 and cholecystokinin
title_sort activity in nodose ganglia neurons after treatment with cp 55,940 and cholecystokinin
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278814/
https://www.ncbi.nlm.nih.gov/pubmed/30512249
http://dx.doi.org/10.14814/phy2.13927
work_keys_str_mv AT johnstonjulianer activityinnodoseganglianeuronsaftertreatmentwithcp55940andcholecystokinin
AT freemankimberlyg activityinnodoseganglianeuronsaftertreatmentwithcp55940andcholecystokinin
AT edwardsgaylenl activityinnodoseganglianeuronsaftertreatmentwithcp55940andcholecystokinin